Showing results (31-40 of 37) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Lancet (London, England)|April 10, 2007
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsBonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, et al.The New England Journal of Medicine|March 15, 2003
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaJacob P Lalezari, Keith Henry, Mary O'Hearn, et al.AIDS Research and Human Retroviruses|August 9, 2002
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adultsJ Michael Kilby, Jacob P Lalezari, Joseph J Eron, et al.HIV Clinical Trials|June 21, 2011
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patientsDaniel J Skiest, Calvin Cohen, Karam Mounzer, et al.AIDS Patient Care and Stds|August 23, 2007
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretroviralsJacques Reynes, Keikawus Arastéh, Bonaventura Clotet, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeksBenoit Trottier, Sharon Walmsley, Jacques Reynes, et al.Pageof 4